Arrowhead Pharmaceuticals, Inc.
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
Granted 2.47M · Sold 1.44M
Granted 445.0K · Sold 184.9K
Granted 295.0K · Sold 186.9K
Granted 365.0K · Sold 258.0K
Granted 135.0K · Sold 67.0K
Granted 75.0K · Sold 13.1K
Granted 75.5K · Sold 18.4K
Granted 29.3K · Bought 655 · Sold 20.8K
Granted 53.8K · Sold 20.8K
Granted 53.8K · Sold 22.8K
Granted 53.8K · Sold 27.5K
Granted 24.6K · Bought 5.4K · Sold 3.0K
Granted 46.2K
Granted 47.4K · Sold 27.1K
Granted 53.8K · Sold 34.2K
Granted 14.3K · Sold 4.5K
Granted 11.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Anzalone Christopher RichardChief Executive Officer, Director · 83 transactions | +13.6% | 3.80M | 2.47M | — | 1.44M |
| O'Brien PatrickCOO · 55 transactions | +37.4% | 472.8K | 445.0K | — | 184.9K |
| Myszkowski Kenneth AllenChief Financial Officer · 19 transactions | +4.8% | 465.4Kas of Jan 2025 | 295.0K | — | 186.9K |
| Hamilton James CChief Medical Officer · 52 transactions | +79.8% | 227.0K | 365.0K | — | 258.0K |
| San Martin JavierChief Medical Officer · 12 transactions | +57.9% | 206.0Kas of Jan 2024 | 135.0K | — | 67.0K |
| Apel Daniel JosephChief Financial Officer · 4 transactions | — | 172.8K | 75.0K | — | 13.1K |
| Oliver TracieChief Commercial Officer · 5 transactions | — | 127.1Kas of Jul 2024 | 75.5K | — | 18.4K |
| Given Douglas BDirector · 12 transactions | +8.1% | 124.2Kas of Dec 2024 | 29.3K | 655 | 20.8K |
| Perry Michael SDirector · 9 transactions | +36.7% | 123.1K | 53.8K | — | 20.8K |
| Ferrari MauroDirector · 10 transactions | +72.8% | 69.1K | 53.8K | — | 22.8K |
| Waddill William D.Director · 16 transactions | +87% | 56.6K | 53.8K | — | 27.5K |
| Lu HongboDirector · 12 transactions | — | 52.0K | 24.6K | 5.4K | 3.0K |
| Ingram Douglas SDirector · 2 transactions | — | 46.2K | 46.2K | — | — |
| Vakiener VictoriaDirector · 13 transactions | — | 37.7K | 47.4K | — | 27.1K |
| Olukotun Adeoye YDirector · 16 transactions | +140% | 33.6K | 53.8K | — | 34.2K |
| De Backer MarianneDirector · 5 transactions | -78.6% | 4.6Kas of Jan 2023 | 14.3K | — | 4.5K |
| Cohen Matthew GregoryDirector · 1 transaction | — | 0 | 11.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -2.32M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.